Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Cosopt; Cosopt Mini; Cosopt PF; L-671152/timolol; MK-507/timolol

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co; Merck Sharp & Dohme
  • Developer Akorn; Merck & Co; Merck Sharp & Dohme; Purdue Pharma; Santen Pharmaceutical; Sidus
  • Class Antiglaucomas; Propanolamines; Sulfonamides; Thiadiazoles; Thiophenes
  • Mechanism of Action Beta-adrenergic receptor antagonists; Carbonic anhydrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Glaucoma; Ocular hypertension

Most Recent Events

  • 09 Dec 2015 COSOPT® licensed to Purdue Pharma in Canada
  • 10 Mar 2015 Japanese Ministry of Health, Labour and Welfare approves a preservative free formulation of dorzolamide/timolol for treatment of Glaucoma and Ocular hypertension in Japan
  • 15 Aug 2014 Santen Pharmaceutical files for approval of a preservative-free formulation of Dorzolamide/timolol in Japan
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top